Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet): A survey of chronically infected individuals

AIDS

Volumn 17, Issue 7, 2003, Pages 1063-1069

  Brindeiro, Rodrigo M ^a   Diaz, Ricardo S ^b   Sabino, Ester C ^c   Morgado, Mariza G ^b   Pires, Ivone L ^d,e   Brigido, Luís ^f   Dantas, Maria C ^g   Barreira, Draurio ^g   Teixeira, Paulo R ^g   Tanuri, Amilcar ^a,b  

^a Dept of Technological Development   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f INSTITUTO ADOLFO LUTZ   (Brazil)

^g MINISTÉRIO DA SAÚDE   (Brazil)

Author keywords

Drug resistance; Genotyping; HIV surveillance

Indexed keywords

NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; BRAZIL; FEMALE; GEOGRAPHIC DISTRIBUTION; HETEROSEXUALITY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; PATIENT COUNSELING; PHYLOGENY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; SEQUENCE ANALYSIS; VIRUS LOAD; VIRUS MUTATION;

ADULT; BRAZIL; CHRONIC DISEASE; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MUTATION; PREVALENCE; RISK FACTORS;

EID: 0037541205     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200305020-00016     Document Type: Article

References (56)

1. Carpenter CCJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1998. JAMA 1998, 280:78-86.
2. Shafer RW, Winters MA, Palmer S, Merigan TC. Multiple concurrent reverse transcriptase and protease mutations multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med 1998, 128:906-911.
3. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999, 353:863-868.
4. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295-1300.
5. Ross L, Johnson M, DeMasi R, Liao Q, Graham N, Shaefer M, et al. Viral genetic heterogeneity in HIV-1 infected individuals is associated with increasing use of HAART and higher viremia. AIDS 2000, 14:813-819.
6. Conway B, Wainberg MA, Hall D, Harris M, Reiss P, Cooper D, et al. Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine. AIDS 2001, 15:1269-1274
7. Vella S. and Palmisano L. Antiviral therapy: state of the HAART. Antiviral Res 2000, 45:1-7.
8. Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 1999, 354:729-733.
9. Yerly S, Race E, Vora S, Rizzardi P, Chave JP, Flepp M, et al. HIV drug resistance and molecular epidemiology in patients with primary HIV infection. In Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 754].
10. Chaix ML, Harzic M, Masquelier B, Pellegrin I, Meyer L, Costagliola D, et al. Prevalence of genotypic drug resistance among French patients infected during the year 1999. In Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 755].
11. Tamalet C, Pasquier C, Yahi N, Colson P, Martin LP, Lepeu G, et al. Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV-1 infection. J Med Virol 2000, 61:181-186.
12. Duwe S, Brunn M, Altman D, Hamouda O, Schmidt B, Walter H, et al. Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients from the German seroconverter study. J Acquir Immune Defic Syndr 2001, 26:266-273.
13. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. Br Med J 2001, 322:1087-1088.
14. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral drug susceptibility and response to initial therapy among recently HIV-infected subjects in North America. Antiviral Ther 2001, 6(suppl 1):21.
15. Boden D, Hurley A, Zhang L, Cao Y, Guo Y, Jones E, et al. HIV-1 drug resistance in newly infected individuals. JAMA. 1999, 282:1135-1141.
16. Brodine SK, Shaffer RA, Starkey MJ, Tasker SA, Gilcrest JL, Louder MK, et al. Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. Ann Intern Med 1999, 131:502-506.
17. Briones C, Perez-Olmeda M, Rodriguez C, Romero J, Hertogs K, Soriano V. Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid. J Acquir Immune Defic Syndr 2001, 26:145-150.
18. Puig T, Perez-Olmeda M, Rubio A, Ruiz L, Briones C, Franco JM, et al. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. AIDS 2000, 14:727-732.
19. Gomez-Cano M, Rubio A, Puig T, Perez-Olmeda M, Ruiz L, Soriano V, et al. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. AIDS 1998,12:1015-1020.
20. Weinstock H, Respess R, Heneine W, Petropoulos CJ, Hellmann NS, Luo CC, et al. Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconversters in the United States, 1993-1998. J Infect Dis 2000, 182:330-333.
21. Zaidi I, Weinstock H, Woods T, Petropoulos CJ, Hellmann NS, Luo CC, et al. Prevalence of mutations associated with antiretroviral drug resistance among HIV-1-infected persons in 10 US cities, 1997-2000. Antiviral Ther 2001, 6(suppl 1):118.
22. Kijak GH, Pampuro SE, Avila MM, Zala C, Cahn P, Wainberg MA, Salomon H. Resistance profiles to antiretroviral drugs in HIV-1 drug-naive patients in Argentina. Antiviral Ther 2001, 6:71-77.
23. Cesaire R, Dos Santos G, Abel S, Bera O, Sobesky G, Cabie A. Drug resistance mutations among HIV-1 strains from antiretroviral-naive patients in Martinique, French West Indies. J Acquire Immune Defic Syndr 1999, 22:401-405.
24. Delgado E, Leon-Ponte M, Villahermosa ML, Cuevas MT, Deibis L, Echeverria G, et al. Analysis of HIV type 1 protease and reverse transcriptase sequences from Venezuela for drug resistance-associated mutations and subtype classification: A UNAIDS study. AIDS Res Hum Retroviruses 2001, 17:753-758.
25. Becker PG, Mellquist JL, Guay L, Mmiro F, Ndugwa C, Kataaha P, et al. Analysis of HIV type 1 protease and reverse transcriptase in antiretroviral drug-naive Ugandan adults. AIDS Res Hum Retroviruses 2000, 16:807-813.
26. Vergne L, Peeters M, Mpoudi-Ngole E, Bourgeois A, Liegeois F, Toure-Kane C, et al. Genetic diversity of protease and reverse transcriptase sequences in non-subtype B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 2000, 38:3919-3925.
27. Bongertz V, Bou-Habib DC, Brigido LF, Caseiro M, Chequer PJ, Couto-Fernandez JC, et al. HIV-1 diversity in Brazil: genetic, biologic, and immunologic characterization of HIV-1 strains in three potential HIV vaccine evaluation sites. J Acquir Immune Defic Syndr 2000, 23:184-193.
28. Caride E, Brindeiro R, Hertogs K, Larder B, Dehertogh P, Machado E, et al. Drug-resistance reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type 1 found in Brazilian patients failing HAART. Virology 2000, 275:107-115.
29. Cornelissen M, Kampinga G, Zorgdrager F, for the UNAIDS Network for HIV Isolation and Characterization. Human immunodeficiency virus type 1 subtypes defined by env show high frequency of recombinant gag genes. J Virol 1996, 70:8209-8212.
30. Couto-Fernandez JC, Morgado MG, Bongertz V, Tanuri A, Andrade T, Brites C, et al. HIV-1 subtyping in Salvador, Bahia, Brazil: a city with African sociodemographic characteristics. J Acquir Immune Defic Syndr 1999, 22:288-293.
31. Sabino EC, Shpaer EG, Morgado MG, Korber BT, Diaz RS, Bongertz V, et al. Identification of human immunodeficiency virus type 1 envelope genes recombinant between subtypes B and F in two epidemiologically linked individuals from Brazil. J Virol 1994, 68:6340-6346.
32. Tanuri A, Vicente AC, Otsuki K, Ramos CA, Ferreira OC Jr, Schechter M, et al. Genetic variation and susceptibilities to protease inhibitors among subtypes B and F isolates in Brazil. Antimicrob Agents Chemother 1999, 43:253-258.
33. Stuyver L, Wyseur A, Rombout A, Lowagie J, Scarcez T, Verhofstede C, et al. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother 1997, 41:284-291.
34. Gaschen B, Kuiken C, Korber B, Foley F. Retrieval and on-the-fly alignment of sequence fragments from the HIV database. Bioinformatics 2001, 17:415-418.
35. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucl Acids Res 1994, 22:4673-4680.
36. Smith SW, Overbeek CR, Woese W, Gilbert W, Gillevet PM. The genetic data environment: an expandable GUI for multiple sequence analysis. Comput Appl Biosci 1994, 10:671-675.
37. Swofford D. PAUP 4.0: Phylogenetic Analysis using Parsimony (and Other Methods), 4.0b2a. Sunderland, MA: Sinauer; 1999.
38. Hirsch MS, Brun-Vezinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, et al. Antiretroviral drug resistance testing in adult HIV-1 infection. JAMA 2000, 283:2417-2426.
39. Hirsch MS, Conway B, D'Aquila RT, Johnson VA, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. JAMA 1998, 279:1984-1991.
40. Ramos A, Tanuri A, Schechter M, Rayfield MA, Hu DJ, Cabral MC, et al. Dual and recombinant infections: an integral part of the HIV-1 epidemic in Brazil. Emerg Infect Dis 1999, 5:65-74.
41. Pieniazek D, Peralta JM, Ferreira JA, Krebs JW, Owen SM, Sion FS, et al. Identification of mixed HIV-1/HIV-2 infections in Brazil by polymerase chain reaction. AIDS 1991, 5:1293-1299.
42. Potts KE, Kalish ML, Lott T, Orloff G, Luo CC, Bernard MA, et al. Genetic heterogeneity of the V3 region of the HIV-1 envelope glycoprotein in Brazil. AIDS 1993, 7:1191-1197.
43. Tanuri A, Swanson P, Devare S, Berro OJ, Savedra A, Costa LJ, et al. HIV-1 subtypes among blood donors from Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 20:60-66.
44. Tambussi G, Boeri E, Carrera P, Gianotti N, Lazzarin A. Prevalence of mutation associated with resistance to nucleoside analogues in a cohort of naive HIV-1 positive subjects during the period 1984-1997. J Biol Regu. Homeost Agents 1998, 12(suppl 1-2):32-34.
45. Dietrich U, Raudonat I, Wolf E, Jager H, Husak R, Orfanos CE, et al. Indication for increasing prevalence of resistance mutations for protease inhibitors in therapy-naive HIV-1-positive German patients. AIDS 1999, 13:2304-2305.
46. van Vaerenbergh K, Debaisieux L, de Cabooter N, Declercq C, Desmet K, Fransen K, et al. Prevalence of genotypic resistance among antiretroviral drug-naive HIV-1 infected patients in Belgium. Antiviral Ther 2001, 6:63-70.
47. Little SJ, Daar ES, D'Aquila RT, Keiser, PH, Connick E, Whitcomb JM, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA. 1999, 282:1142-1149.
48. Trabaud MA, Leriche KG, Corinne R, Keiser PH, Connick E, Whitcomb JM, et al. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: High proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus. J Med Virol 2000, 61:352-359.
49. Salomon H, Wainberg MA, Brenner B, Quan Y, Rouleau D, Cote P, et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. AIDS 2000, 14:F17-F23.
50. Brenner B, Wainberg MA, Salomon H, Rouleau D, Dascal A, Spira B, et al. Resistance to antiretroviral drugs in patients with primary HIV-1 infection. Int J Antimicrob Agents 2000, 16:429-434.
51. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002, 347:385-394.
52. Pieniazek D, Rayfield M, Hu DJ, Nkengasong J, Wiktor SZ, Downing R, et al. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. AIDS 2000, 14:1-7.
53. Frater J, Dunn D, Weber JN, McClure MO. Association between secondary mutations in human immunodeficiency virus type 1 protease and therapeutic outcome. J Infect Dis. 2002, 185:1376.
54. Clevenbergh P, Cua E, Dam E, Durant J, Schmit JC, Boulme R, et al. Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naive HIV-infected patients. HIV Clin Trials 2002, 3:36-44
55. Osmanov S, Heyward WL, Esparza J and the World Health Organization Network for HIV Isolation and Characterization. Summary of a pilot study. AIDS Res Hum Retroviruses 1994 10:1325-1326.
56. Durant J, Clevenberg P, Halfon P, Delgiudice P, Porsin S, Simonet P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999, 353:2195-2199.